144 related articles for article (PubMed ID: 10696255)
1. The role of photodynamic therapy in the treatment of recurrent superficial bladder cancer.
Walther MM
Urol Clin North Am; 2000 Feb; 27(1):163-70. PubMed ID: 10696255
[TBL] [Abstract][Full Text] [Related]
2. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial.
Hudson MA; Ratliff TL; Gillen DP; Haaff EO; Dresner SM; Catalona WJ
J Urol; 1987 Aug; 138(2):295-8. PubMed ID: 3298694
[TBL] [Abstract][Full Text] [Related]
3. Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors.
Herr HW; Pinsky CM; Whitmore WF; Sogani PG; Oettgen HF; Melamed MR
Urology; 1985 Feb; 25(2):119-23. PubMed ID: 3881870
[TBL] [Abstract][Full Text] [Related]
4. [BCG immunotherapy in the treatment of superficial bladder tumors].
Samodai L; Drinóczy M; Kolozsy Z; Mohácsi L; Dauda G; Porkoláb Z
Orv Hetil; 1986 Oct; 127(40):2441-6. PubMed ID: 3537907
[No Abstract] [Full Text] [Related]
5. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
[TBL] [Abstract][Full Text] [Related]
6. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
[No Abstract] [Full Text] [Related]
7. Superficial bladder cancer. Risk of recurrence and potential role for interferon therapy.
Torti FM; Lum BL
Cancer; 1987 Feb; 59(3 Suppl):613-6. PubMed ID: 2433019
[TBL] [Abstract][Full Text] [Related]
8. [Immunotherapy in superficial bladder carcinoma].
Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ
Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study.
Berger AP; Steiner H; Stenzl A; Akkad T; Bartsch G; Holtl L
Urology; 2003 Feb; 61(2):338-41. PubMed ID: 12597942
[TBL] [Abstract][Full Text] [Related]
10. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.
Pinsky CM; Camacho FJ; Kerr D; Geller NL; Klein FA; Herr HA; Whitmore WF; Oettgen HF
Cancer Treat Rep; 1985 Jan; 69(1):47-53. PubMed ID: 3881177
[TBL] [Abstract][Full Text] [Related]
11. Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study.
Witjes JA; Fransen MP; van der Meijden AP; Doesburg WH; Debruyne FM
Urol Int; 1993; 51(2):67-72. PubMed ID: 8351757
[TBL] [Abstract][Full Text] [Related]
12. Intravesical therapy: does it affect the natural history of superficial bladder cancer?
Lamm DL; Griffith JG
Semin Urol; 1992 Feb; 10(1):39-44. PubMed ID: 1565903
[No Abstract] [Full Text] [Related]
13. Intravesical therapy for superficial bladder cancer.
Malkowicz SB
Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
[TBL] [Abstract][Full Text] [Related]
14. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
15. Response criteria for phase III studies of superficial bladder cancer.
Schröder FH; Sylvester R; Gustafson H; Kawai T; Kurth KH; Matsuda M; Miyakawa M; Newling DW; Studer E
Prog Clin Biol Res; 1986; 221():311-21. PubMed ID: 3543946
[No Abstract] [Full Text] [Related]
16. Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium.
Manyak MJ; Ogan K
J Endourol; 2003 Oct; 17(8):633-9. PubMed ID: 14622483
[TBL] [Abstract][Full Text] [Related]
17. [Intravesical bacillus Calmette-Guerin instillation therapy of recurrent superficial bladder carcinomas resistant to intravesical anti-cancer chemotherapy].
Takeuchi S; Kihara K; Higashi Y; Fukui I; Oshima H
Hinyokika Kiyo; 1989 Apr; 35(4):577-81. PubMed ID: 2735262
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
[TBL] [Abstract][Full Text] [Related]
19. BCG in management of superficial bladder cancer.
Guinan P; Crispen R; Rubenstein M
Urology; 1987 Dec; 30(6):515-9. PubMed ID: 3318088
[TBL] [Abstract][Full Text] [Related]
20. Management of superficial transitional cell carcinoma of the bladder.
Fleischmann J; Goldberg G
Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
